{"protocolSection": {"identificationModule": {"nctId": "NCT01747629", "orgStudyIdInfo": {"id": "ABS-AS-304"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Efficacy of Inhaled Albuterol Spiromax\u00ae in Subjects With Persistent Asthma With Steady State Pharmacokinetics", "officialTitle": "A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax\u00ae Versus Placebo in Subjects 12 Years and Older With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-12-07", "studyFirstSubmitQcDate": "2012-12-07", "studyFirstPostDateStruct": {"date": "2012-12-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-05-02", "resultsFirstSubmitQcDate": "2015-05-04", "resultsFirstPostDateStruct": {"date": "2015-05-21", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-05-08", "dispFirstSubmitQcDate": "2014-05-08", "dispFirstPostDateStruct": {"date": "2014-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-28", "lastUpdatePostDateStruct": {"date": "2015-06-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax\u00ae versus placebo in subjects with persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "dry powder inhaler", "short-acting beta2-agonist", "SABA", "bronchoconstriction", "bronchodilation", "bronchodilator", "metered dose inhaler", "Albuterol Spiromax\u00ae"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 160, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo MDPI", "type": "PLACEBO_COMPARATOR", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.", "interventionNames": ["Drug: Placebo MDPI"]}, {"label": "Albuterol MDPI", "type": "EXPERIMENTAL", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.", "interventionNames": ["Drug: Albuterol MDPI"]}], "interventions": [{"type": "DRUG", "name": "Placebo MDPI", "description": "Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.", "armGroupLabels": ["Placebo MDPI"], "otherNames": ["Placebo Spiromax\u00ae"]}, {"type": "DRUG", "name": "Albuterol MDPI", "description": "Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.", "armGroupLabels": ["Albuterol MDPI"], "otherNames": ["ProAir\u00ae RespiClick, Albuterol Spiromax\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 1, Day 8 and Day 85"}], "secondaryOutcomes": [{"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 1"}, {"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 8"}, {"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 85"}, {"measure": "Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "Day 1 to Day 93"}, {"measure": "Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group", "description": "Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint. HEENT = head, eyes, ears, nose, throat.", "timeFrame": "Day 1 (Baseline), Day 85"}, {"measure": "Participants With Clinically Significant Vital Sign Assessments", "description": "For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 \u00b1 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 \u00b1 5 and -5 minutes, then post-dose at 30 (\u00b15) minutes, 1hr (\u00b1 10 min), 2hr (\u00b1 10 min), 3hr (\u00b1 10 min), 4hr (\u00b1 10 min), 5hr (\u00b1 10 min) and 6 hr (\u00b1 10 min).\n\nSerial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:\n\nSystolic blood pressure: \\> 160 beats/minute Diastolic blood pressure: \\>100 beats/minute Heart rate: \\>120 beats/minute", "timeFrame": "Days 8 and 85"}, {"measure": "Maximum Observed Plasma Drug Concentration (Cmax) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "timeFrame": "Days 1 and 8"}, {"measure": "Time to Observed Peak Plasma Concentration (Tmax) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "timeFrame": "Days 1 and 8"}, {"measure": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) up to 6 Hours Post-dose (AUC0-6) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).\n\nAUC0-6 on Day 8 is not from pre-dose but at steady state.", "timeFrame": "Days 1 and 8"}, {"measure": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (AUC0-t) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).\n\nAUC0-t on Day 8 is not from pre-dose but at steady state.", "timeFrame": "Days 1 and 8"}, {"measure": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Infinity Post-dose(AUC0-inf) for Albuterol on Day 1", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "timeFrame": "Day 1"}, {"measure": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose(AUC0-24) for Albuterol on Day 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "timeFrame": "Day 8"}, {"measure": "Terminal Plasma Half-life (t1/2) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "timeFrame": "Days 1 and 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent/assent\n* At least 12 years of age at screening\n* General good health\n* Persistent asthma for \u22653 months, with an FEV1 50-80% predicted and \u226515% reversibility\n* Taking inhaled corticosteroids at a stable dose (\u2264 equivalent of 500mcg of fluticasone propionate/day) for at least 4 weeks prior to the Screening Visit.\n* Ability to perform spirometry in an acceptable manner as per protocol guidelines\n* Other inclusion criteria apply\n\nExclusion Criteria:\n\n* A known hypersensitivity to albuterol or any of the excipients in the formulations.\n* History of a respiratory infection or disorder that has not resolved within 1 week preceding the Screening Visit (SV).\n* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.\n* Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.\n* Hospitalization due to asthma exacerbation 2 or more times in the past year\n* Initiation of immunotherapy or dose escalation during the study period\n* Other exclusion criteria apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Project Leader", "affiliation": "Teva Respiratory R&D", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 10225", "city": "Costa Mesa", "state": "California", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Teva Investigational Site 10250", "city": "Encinitas", "state": "California", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Teva Investigational Site 10230", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 10255", "city": "Palmdale", "state": "California", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Teva Investigational Site 10231", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Teva Investigational Site 10252", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Teva Investigational Site 10242", "city": "Rolling Hills Estates", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Teva Investigational Site 10238", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Teva Investigational Site 10243", "city": "San Jose", "state": "California", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Teva Investigational Site 10247", "city": "Miami Lakes", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.90871, "lon": -80.30866}}, {"facility": "Teva Investigational Site 10239", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Teva Investigational Site 10234", "city": "Tampa", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Teva Investigational Site 10253", "city": "Bangor", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Teva Investigational Site 10257", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Teva Investigational Site 10254", "city": "White Marsh", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Teva Investigational Site 10235", "city": "Fall River", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Teva Investigational Site 10236", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Teva Investigational Site 10226", "city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Teva Investigational Site 10233", "city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Teva Investigational Site 10241", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Teva Investigational Site 10229", "city": "Bellevue", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Teva Investigational Site 10227", "city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Teva Investigational Site 10244", "city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Teva Investigational Site 10248", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 10249", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 10232", "city": "Eugene", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Teva Investigational Site 10259", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 10237", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Teva Investigational Site 10240", "city": "Bethlehem", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.62593, "lon": -75.37046}}, {"facility": "Teva Investigational Site 10246", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Teva Investigational Site 10256", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Teva Investigational Site 10251", "city": "Rock Hill", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.92487, "lon": -81.02508}}, {"facility": "Teva Investigational Site 10228", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Teva Investigational Site 10258", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 10245", "city": "Seattle", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "referencesModule": {"references": [{"pmid": "26369589", "type": "DERIVED", "citation": "Raphael G, Taveras H, Iverson H, O'Brien C, Miller D. Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. J Asthma. 2016;53(2):187-93. doi: 10.3109/02770903.2015.1070862. Epub 2015 Sep 15."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 361 patients screened, 158 were excluded on the basis of inclusion criteria, 5 on the basis of exclusion criteria, 13 withdrew consent, 1 patient was noncompliant, 2 patients were lost to follow-up before the baseline visit, 7 patients had other reasons, and 15 failed to meet the randomization criteria at the end of the run-in period.", "groups": [{"id": "FG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "FG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "75"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "comment": "Safety set and full analysis set", "numSubjects": "84"}, {"groupId": "FG001", "comment": "Safety set and full analysis set", "numSubjects": "75"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "69"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Inclusion criteria not met", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Not treated", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized analysis set", "groups": [{"id": "BG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "BG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "160"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.7", "spread": "15.94"}, {"groupId": "BG001", "value": "40.0", "spread": "18.06"}, {"groupId": "BG002", "value": "38.2", "spread": "16.99"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "12-17 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "31"}]}]}, {"title": "18-64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "125"}]}]}, {"title": "65+ years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "81"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "79"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "125"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "14"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "146"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.8", "spread": "22.76"}, {"groupId": "BG001", "value": "79.6", "spread": "20.75"}, {"groupId": "BG002", "value": "79.7", "spread": "21.77"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "167.8", "spread": "9.23"}, {"groupId": "BG001", "value": "169.8", "spread": "10.93"}, {"groupId": "BG002", "value": "168.7", "spread": "10.08"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.1", "spread": "6.48"}, {"groupId": "BG001", "value": "27.4", "spread": "5.90"}, {"groupId": "BG002", "value": "27.7", "spread": "6.21"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set included all participants in the intent-to-treat population who received at least 1 dose of study medication and had at least 1 post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L*hr", "timeFrame": "Day 1, Day 8 and Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.38", "spread": "0.114"}, {"groupId": "OG001", "value": "1.30", "spread": "0.120"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "mixed-model repeated-measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "1.24", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.163"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.58", "lowerLimit": "0.24", "upperLimit": "0.92"}, {"groupId": "OG001", "value": "1.63", "lowerLimit": "1.27", "upperLimit": "1.99"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.55", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.249"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set of participants with data at the time point", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "74"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "lowerLimit": "0.08", "upperLimit": "0.66"}, {"groupId": "OG001", "value": "1.15", "lowerLimit": "0.84", "upperLimit": "1.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.35", "ciUpperLimit": "1.19", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.212"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set of participants with data at the time point", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "lowerLimit": "-0.05", "upperLimit": "0.44"}, {"groupId": "OG001", "value": "1.12", "lowerLimit": "0.86", "upperLimit": "1.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "1.28", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.180"}]}, {"type": "SECONDARY", "title": "Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 to Day 93", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Severe adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Treatment-related adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Other serious adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Withdrawn from study due to adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group", "description": "Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint. HEENT = head, eyes, ears, nose, throat.", "populationDescription": "Safety population. Only participants with both baseline and endpoint physical examination findings are summarized.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 (Baseline), Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"title": "General appearance Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "72"}]}]}, {"title": "General appearance Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "General appearance Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "General appearance Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "HEENT Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "52"}]}]}, {"title": "HEENT Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "HEENT Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "HEENT Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Chest and Lungs Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "64"}]}]}, {"title": "Chest and Lungs Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Chest and Lungs Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Chest and Lungs Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Heart Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "70"}]}]}, {"title": "Heart Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Heart Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Heart Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Abdomen Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "71"}]}]}, {"title": "Abdomen Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Abdomen Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Abdomen Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Musculoskeletal Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "72"}]}]}, {"title": "Musculoskeletal Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Musculoskeletal Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Musculoskeletal Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Skin Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "63"}]}]}, {"title": "Skin Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Skin Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Skin Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Lymph nodes Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "74"}]}]}, {"title": "Lymph nodes Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymph nodes Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymph nodes Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "74"}]}]}, {"title": "Neurological Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Clinically Significant Vital Sign Assessments", "description": "For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 \u00b1 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 \u00b1 5 and -5 minutes, then post-dose at 30 (\u00b15) minutes, 1hr (\u00b1 10 min), 2hr (\u00b1 10 min), 3hr (\u00b1 10 min), 4hr (\u00b1 10 min), 5hr (\u00b1 10 min) and 6 hr (\u00b1 10 min).\n\nSerial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:\n\nSystolic blood pressure: \\> 160 beats/minute Diastolic blood pressure: \\>100 beats/minute Heart rate: \\>120 beats/minute", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Days 8 and 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"title": "Systolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Diastolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Heart rate - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Observed Plasma Drug Concentration (Cmax) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Days 1 and 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG001", "value": "347.2", "spread": "146.6"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG001", "value": "499.1", "spread": "154.3"}]}]}]}, {"type": "SECONDARY", "title": "Time to Observed Peak Plasma Concentration (Tmax) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hour", "timeFrame": "Days 1 and 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG001", "value": "0.48", "lowerLimit": "0.18", "upperLimit": "4.95"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG001", "value": "0.44", "lowerLimit": "0.25", "upperLimit": "2.02"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) up to 6 Hours Post-dose (AUC0-6) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).\n\nAUC0-6 on Day 8 is not from pre-dose but at steady state.", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*hr/mL", "timeFrame": "Days 1 and 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG001", "value": "1325", "spread": "646"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG001", "value": "2163", "spread": "825"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (AUC0-t) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).\n\nAUC0-t on Day 8 is not from pre-dose but at steady state.", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*hr/mL", "timeFrame": "Days 1 and 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG001", "value": "1747", "spread": "785"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG001", "value": "2165", "spread": "839"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Infinity Post-dose(AUC0-inf) for Albuterol on Day 1", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*hr/mL", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "2278", "spread": "869"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose(AUC0-24) for Albuterol on Day 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*hr/mL", "timeFrame": "Day 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "3605", "spread": "1189"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Plasma Half-life (t1/2) for Albuterol on Days 1 and 8", "description": "Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (\u00b110 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (\u00b15) min, 30 (\u00b15) min, and 1, 2, 3, 4, 5 and 6 hr (\u00b110 min).", "populationDescription": "Pharmacokinetic analysis set representing a subset of participants from the Albuterol MDPI treatment arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour", "timeFrame": "Days 1 and 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG001", "value": "4.7", "spread": "1.3"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG001", "value": "5.7", "spread": "1.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 to Day 93", "eventGroups": [{"id": "EG000", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 75, "otherNumAffected": 9, "otherNumAtRisk": 75}, {"id": "EG001", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 10, "otherNumAtRisk": 84}], "seriousEvents": [{"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "Pharyngeal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 75}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 84}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "1-215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}